Dr. rer. nat. Reinhard Maier
Head Clinical Trials Unit (CTU) (operational)
scientist (post doc)
Medizinisches Forschungszentrum, Clinical Trials Unit · Management
Prostatic Artery Embolization vs. conventional TUR-P in the Treatment of Benign Prostatic Hyperplasia: A prospective randomized trial
Feb 5, 2014
Clinical Studies - Feb 5, 2014 - Apr 5, 2023
Automatically Closed
Project leader: Engeler Daniel, Abt Dominik
Members: Schmid Hans-Peter, Hechelhammer Lukas, Patzl Sigrid, Lengwiler Daniel, Haile Sarah, Maier Reinhard, Schulz Thomas
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer
May 1, 2013The primary objective of this trial is to evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inbibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) and of a chemother...
Clinical Studies - May 1, 2013 - May 1, 2019
Automatically Closed
Project leader: Weder Patrik
Members: Thürlimann Beat, Ruhstaller Thomas, Maier Reinhard, Riniker Salome, Öhlschlegel Christian, Hasler-Strub Ursula
SAKK 22/10: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemothera-py, both followed by T-DM1 in case of progression, in pa-tients with HER2-positive metastatic breast cancer
Apr 29, 2013In der vorliegenden Studie wird eine neue Strategie für die Behandlung des HER2-positiven metastasierenden Brustkrebses untersucht, bei der die Erstlinientherapie aus Herceptin® und Perjeta® besteht und somit chemotherapiefrei ist. Bei Fortschreiten...
Clinical Studies - Apr 29, 2013 - Jun 27, 2015
Automatically Closed
Project leader: Weder Patrik
Members: Ruhstaller Thomas, Hasler-Strub Ursula, Maier Reinhard, Öhlschlegel Christian, Riniker Salome, Kaelin Martin, Hochstrasser Andreas, Thürlimann Beat
Multiepitop Imfpung von Grad III/IV Melanompatienten mit dendritischen Zellen: Bedeutung von Peptidaffinität und -dichte für die optimale Generierung von tumorspezifischen zytotoxischen T-Lymphozyten
Jan 1, 2007Die immunologische Forschung der letzten Jahre hat deutlich gemacht, dass Krebszellen Zielstrukturen, sogenannte Antigene, produzieren, die sie für einen Angriff durch spezifische Immunzellen sensibilisieren. Die effektivste Waffe des Immunsystems ge...
Clinical Studies - Jan 1, 2007 - Dec 31, 2009
Completed
Project leader: Ludewig Burkhard, Gillessen Sommer Silke, Cerny Thomas
Members: Maier Reinhard, Templeton Arnoud
Preventing autoimmune myocarditis through cardiac myosin-specific tolerance
Jan 1, 2007The exact pathological basis of human myocarditis has not yet been sufficiently clarified and therefore, the appropriate treatment has remained a major clinical problem. Assuming that immunopathological damage contributes to the inflammatory nature o...
Fundamental Research - Jan 1, 2007 - Dec 31, 2009
Completed
Project leader: Ludewig Burkhard
Members: Nindl Veronika, Maier Reinhard